

### Taligen's Novel Approach to Complement Regulation

Taligen's founders and scientific collaborators are world-renowned experts in complement system biology, having made some of the groundbreaking discoveries relating to the genetic drivers and biological processes that are now known to cause over-activation of the complement system in many chronic and acute, life-threatening diseases.

- Taligen has a pipeline of novel complement inhibitor proteins that selectively control complement activation on the surfaces of damaged or inflamed tissues
- Taligen closed a \$65 million Series B financing in 2008
- Taligen's lead product is expected to enter clinical development in the 1st half of 2010
- Taligen Therapeutics maintains headquarters and labs in Cambridge, MA


**Taligen has built a management team with world class expertise in:**

- ✓ Complement Biology
- ✓ Protein Design & Engineering
- ✓ Biologics Drug Development

### Stopping Complement Activation on Cell Surfaces

Taligen has developed a proprietary inflammatory tissue targeting technology that leverages natural processes within the complement system and directs Taligen drugs to selectively work on the cell surfaces of inflamed or damaged tissue.

- Taligen drugs stop the cell surface protein interactions that lead to the excessive and abnormal complement activation known to cause many severe, chronic and acute diseases such as PNH, aHUS, AMD, asthma and rheumatoid arthritis.
- Taligen drugs act selectively on cell surfaces of complement activated tissues, thus preserving systemic complement activation and surveillance.



### Management Team

**Abbie Celniker, Ph.D.**  
Chief Executive Officer

**Michael Holers, M.D.**  
Chief Scientific Officer

**Jeffrey Walsh, M.B.A.**  
Chief Business Officer

**Christopher Horvath, D.V.M.**  
Vice President, Preclinical Sciences

**Jill Porter, Ph.D.**  
Vice President,  
Biopharmaceutical Development

### Board of Directors

**Tim Mills, Ph.D.**  
Sanderling Ventures

**Ed Hurwitz**  
Alta Partners

**Nick Galakatos, Ph.D.**  
Clarus Ventures

**Abbie Celniker, Ph.D.**  
Chief Executive Officer, Taligen

### Scientific Advisory Board

**Michael Holers, M.D.**  
Chief Scientific Officer, Taligen





**John Atkinson, M.D.**  
Washington University  
School of Medicine

**K. Frank Austen, M.D.**  
Harvard Medical School and  
Brigham and Women's Hospital

### The Complement Activation Pathway, A New Therapeutic Frontier

- The complement system is one of the most target-rich, yet untapped pathways of inflammation and immune diseases.
- Recent genetic studies have directly tied deficiencies in the complement system to various large market diseases (AMD) and orphan diseases (PNH, aHUS).
- Recent advances in the understanding of the complement system and in the tools and models necessary to precisely regulate complement activation have provided fertile ground for drug development.
- Taligen has built a robust pipeline of complement regulators that take advantage of Taligen’s proprietary cell surface targeting technology and Taligen’s deep understanding of the rich set of targets within the complement system.

### Taligen Product Candidate Pipeline

Product Candidate	Target	Preclinical Validation	Lead Optimization	Preclinical	Phase I
<b>TT30</b> <i>Targeted Fusion Protein</i>	Factor H Replacement	AMD, aHUS/TMA. Autoimmune Diseases			
<b>TA106</b> <i>Humanized Antibody Fragment</i>	Inhibitor of Factor B	AMD, aHUS/TMA. Asthma			
<b>TT31</b> <i>Targeted Fusion Protein</i>	Factor H Replacement	Acute Injury			
<b>TT32</b> <i>Targeted Fusion Protein</i>	Inhibition of all complement pathways	Asthma, Rheumatoid Arthritis			
<b>TT33</b> <i>Targeted Fusion Protein</i>	Downstream selective complement inhibition of MAC	Transplant	